Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.

@article{Mato2016OutcomesOC,
  title={Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.},
  author={Anthony R Mato and Chadi Nabhan and Paul M Barr and Chaitra Ujjani and Brian T. Hill and Nicole Lamanna and Alan Skarbnik and Christina Howlett and Jeffrey Jiayu Pu and Alison Sehgal and Lauren E Strelec and Alexandra Vandegrift and Danielle M Fitzpatrick and Clive S Zent and Tatyana A Feldman and Andre H. Goy and David F. Claxton and Spencer Henick Bachow and Gurbakhash Kaur and Jakub Svoboda and Sunita Dwivedy Nasta and David L. Porter and Daniel J. Landsburg and Stephen J. Schuster and Bruce D Cheson and Pavel Kiselev and Andrew M Evens},
  journal={Blood},
  year={2016},
  volume={128 18},
  pages={2199-2205}
}
B-cell receptor kinase inhibitor (KI) therapy represents a paradigm shift in chronic lymphocytic leukemia (CLL) management, but data on practice patterns after KI discontinuation and optimal sequencing are limited. We conducted a multicenter, retrospective, comprehensive analysis on 178 patients with CLL (ibrutinib = 143; idelalisib = 35) who discontinued KI therapy. We examined responses, toxicity, post-KI therapies, and overall survival (OS). Patients had a median of 3 prior therapies (range… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 39 times over the past 90 days. VIEW TWEETS
27 Citations
25 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Ibrutinib therapy for chronic lymphocytic leukemia (CLL): an analysis of a large cohort of patients treated in routine clinical practice [abstract

  • SA Parikh, KR Chaffee, TG Call
  • Blood
  • 2015
Highly Influential
3 Excerpts

Outcomes of patients with chronic lymphocytic leukemia (CLL) after idelalisib therapy discontinuation [abstract

  • JC Barrientos, M Kaur, A Mark
  • Blood
  • 2015
Highly Influential
3 Excerpts

Outcomes of patients with relapsed/refractory chronic lymphocytic leukemia after ibrutinib discontinuation outside clinical trials: a single institution experience [abstract

  • JD Sandoval-Sus, JC Chavez, S Dalia
  • Blood
  • 2015
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…